Inventories

12 Months Ended

Dec. 31, 2021

Inventory Disclosure [Abstract]

Inventories

Inventories

Inventories consist of the following (dollars in thousands):

	December 31, 2021		December 31, 2020
Raw materials	$	7,325	$	22,208
Work in process	45,711		8,985
Finished goods	32,923		17,132
Total	$	85,959	$	48,325

In May 2021, the Company launched Qelbree for the treatment of ADHD in pediatric patients 6 to 17 years of age in the U.S. Capitalized pre-launch inventory costs for Qelbree were $0 and $19.1 million as of December 31, 2021 and December 31, 2020, respectively.

Inventories include the acquired inventories from the USWM Acquisition and Adamas Acquisition. Refer to Note 3 for further discussion of the Company's acquisitions.